Search for agents for the add-on therapy of multiple sclerosis (MS) that can enhance the effect of first-line MS disease-modifying therapy (DMTs) is a very current issue. Such a boost is needed to reduce the need to switch to second-line DMTs, whose pathogenetic therapy leads to severe side effects in many cases. Curcumin, a natural polyphenol, has immunoregulatory properties and a favorable safety profile. At the same time, micellar forms of curcumin can increase its bioavailability.Objective: to investigate the effect of the micellar form of curcumin on clinical parameters in MS patients receiving first-line DMTs.Material and methods. MS patients (n=40) receiving interferon-β (IFNβ) therapy who showed a suboptimal response were randomly divided into two groups, one group received additional therapy (dietary enrichment for 6 months) with curcumin in micellar form, the second group did not receive dietary curcumin. At the beginning and end of the study, the disease activity (clinical and radiological), the degree of disability on the EDSS scale, the severity of chronic fatigue on the MFIS scale, the quality of life on the SF-36 scale and the level of cytokines (interleukin 6 and IFNγ) in the blood plasma were determined. Adverse events were also recorded during the observation period and the safety of the therapy was assessed based on the results of general and biochemical blood tests.Results. In the group of patients whose diet was enriched with curcumin, quality of life indicators improved both in the physical component (from 50.2±6.4 to 52.5±6.8; p=0.03) and in the psychological component (from 42.9±15.9 to 45.6±15.5; p=0.02). In the group receiving curcumin, the proportion of patients with exacerbations over 6 months also decreased – from 45 to 9 % (p=0.01). After 6 months of dietary enrichment, lower plasma levels of IFNγ were observed in patients receiving curcumin than in the group without dietary enrichment. No adverse events were noted during the observation period.Conclusion. The preliminary results allow us to consider micellar forms of curcumin, which have an acceptable tolerability and safety profile, as a potential additional method to increase the efficacy of first-line DMTs in MS patients with suboptimal response to IFNβ.
1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Рассеянный склероз (РС) — хроническое демиелинизирующее заболевание аутоиммунной природы. Терапия не всегда позволяет замедлить прогрессирование заболевания. В ряде случаев патогенетическая терапия РС приводит к серьезным побочным эффектам, в частности к иммуносупрессии, не позволяющим реализовать весь терапевтический потенциал препаратов, изменяющих течение РС (ПИТРС). В связи с этим актуально исследование потенциального применения при РС средств, обладающих иммунотропными и нейропротективными эффектами, а также благоприятным профилем безопасности. Полифенолы (соединения, содержащие фенольные и гидроксильные группы, часто природного происхождения) обладают способностью модулировать иммунорегуляторные мишени, снижая продукцию различных провоспалительных цитокинов, играющих важную роль в патогенезе РС. Совместное применение с ПИТРС веществ, обладающих благоприятным профилем безопасности и противовоспалительной активностью, а также способных проникать через гематоэнцефалический барьер, таких как полифенолы, может быть одной из перспективных стратегий при терапии РС с целью улучшения качества жизни пациентов. В данном обзоре рассматриваются механизмы действия полифенолов при РС, их применение при экспериментальных моделях РС, а также результаты клинических исследований полифенолов при РС.
21 August 2023 in Neurology, Neuropsychiatry, Psychosomatics
Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease. MS therapy does not always allow slowing of disease progression and also has significant side effects, such as immunosuppressive effects (especially when second-line disease-modifying therapies (DMT) are used). In this context, it is important to explore novel approaches to MS therapy that may improve the therapeutic potential of first line DMTs and reduce the likelihood of switching to switch to second line DMTs. Curcumin is one of the promising candidates for such application. Several anti-inflammatory and neuroprotective effects of curcumin have been reported in the literature, which could be considered for such applications. The favorable safety profile of this compound is also important. Over the past decade, encouraging clinical data have been obtained on the use of curcumin as part of adjunctive therapy for MS. However, to date, there are inadequate clinical studies on the use of curcumin in the therapy of MS. This may be due to the fact that curcumin, like other polyphenols, has low bioavailability, which limits its therapeutic potential. Recently, new highly bioavailable forms of curcumin have been developed (e.g., nanoemulsions). In this regard, it is promising to conduct new clinical trials of curcumin as an adjunctive therapy in MS, especially using its forms with increased bioavailability.
23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To compare the diagnostic criteria of 2006 (DC 2006) and 2015 (DC 2015) in the Russian population of patients with suspected neuromyelitis optica spectrum disorders (NMOSD), with the calculation of their sensitivity, specificity, accuracy and predictive value. Material and methods. We reviewed medical records of suspected NMOSD patients who were therefore examined for the presence of serum autoantibodies targeting the aquaporin-4 water channel protein (AQP4-IgG) in 6 specialized Russian (Nizhny Novgorod and Moscow) medical centers. One hundred patients (78 female), aged 17 to 74 years (mean 38.1±13.3 years), were included. The follow-up period ranged from 4 to 108 months (mean 59.7±31.6 months). Results. During the follow-up the diagnosis of NMOSD was confirmed in 32 people, and 68 patients had diagnoses different from NMOSD. At the disease onset, 68.8% of patients were seropositive for AQP4-IgG. The mean time for confirming NMOSD diagnosis was 15.2±14.2 months. At the disease onset, 36% of patients fulfilled the DC 2015, the diagnosis was subsequently confirmed in 77.8% out of them. 26% of the patients fulfilled the DC 2006, the diagnosis was subsequently confirmed in 84.6% out of them. The sensitivity of DC 2006/DC 2015 was 69%/88%, specificity 94%/88%, accuracy 86%/88%, negative predictive value 85%/94%, positive predictive value 86%/78%. Conclusion. The specificity, sensitivity and accuracy of modern diagnostic criteria for NMOSD In Russian patients is comparable to those obtained in foreign studies. DC 2015 helps to diagnose NMOSD earlier than DC 2006, but they have a lower specificity.
8 August 2025 in Meditsinskiy sovet = Medical Council
Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.
Introduction. The etiology of multiple sclerosis (MS) remains unknown. According to the current consensus, susceptibility to MS is due to an elaborate interaction between genetic predisposition and multifactorial environmental factors, including vitamin D deficiency, smoking, inflammatory diet, psychoemotional stress, and infections. With regard to the infectious component, for decades, MS has been associated with a prior infection with the Epstein-Barr virus (EBV). However, it remains unclear why only a limited proportion of the numerous EBV-infected population develop MS.Objective. To discuss the factors of interaction between the immune system and EBV that predispose to the development of MS, as well as to analyze the possibilities of their use as therapeutic targets for the prevention and treatment of MS.Discussion. The results of a recent large epidemiologic study have provided new evidence for the association between EBV and MS. It has also been shown that cross-reacting antibodies to myelin sheath antigens can be detected in the blood of patients with EBV. However, most patients with EBV do not develop MS. This is probably due to the elimination of autoreactive cells. Natural killer (NK) cells play a particularly important role in this process. In MS, NK-mediated elimination of autoreactive B cells may be impaired. In this regard, an add-on therapy of MS aimed at controlling EBV-induced autoimmune responses appears promising.Conclusions. Reduced cytotoxic activity of NK cells against cells that show cross-reactivity to EBV antigens and components of the myelin sheath is among the factors of interaction of the immune system with EBV that contribute to MS development. As an add-on therapy for MS, it may be reasonable to use agents that reduce the presence of EBV in the organism and have a favorable safety profile (e.g., curcumin and quercetin). The search for agents that can improve immunological control of autoreactive cells is also promising. Such agents may include compounds that are capable of enhancing the activity of NK cells, for instance, urolithin A, curcumin, and alloferon.